Skip to main content
SpringerLink
Log in
Book cover

Recent Developments in Graves’ Ophthalmopathy pp 89–100Cite as

Thyroid management in Graves’ ophthalmopathy

  • Chapter

  • 95 Accesses

Abstract

There is a close temporal relationship between the occurrence of Graves’ thyroid disease (GTD) and the onset of Graves’ ophthalmopathy (Fig. 1).1 Both Gorman et al., and Wiersinga et al, found that in approximately 3/4 of the patients both manifestations occurred within 18 months of eachother.2,3 In the majority, the eye signs develop after the first signs of hyperthyroidism. Although clinically manifest ophthalmopathy is seen in only appr. 35% of the patients with Graves’ hyperthyroidism, subclinical evidence for orbital disease is present in almost all patients.1 This close association has always been the most pertinent reason to think that the ophthalmopathy and the thyroid disorder are actually two manifestations of the same condition: Graves’ disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burch H, Wartofsky L. Graves’ ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747–793.

    PubMed  CAS  Google Scholar 

  2. Gorman CA. Temporal relationship between onset of Graves’ ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc 1983; 58: 515–519.

    PubMed  CAS  Google Scholar 

  3. Wiersinga WM, Smit T, Van der Gaag R, Koornneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest 1988; 11: 615–619.

    PubMed  CAS  Google Scholar 

  4. Volpe R. Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signalling: a review. Thyroid 1994; 2: 217–223.

    Article  Google Scholar 

  5. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A. Relationship between Graves’ ophthalmopathy and type of treatment of Graves’ hyperthyroidism. Thyroid 1992; 2: 171–178.

    Article  PubMed  CAS  Google Scholar 

  6. Volpe R. Immunoregulation in autoimmune thyroid disease. N Engl J Med 1987; 316: 44–46.

    Article  PubMed  CAS  Google Scholar 

  7. Papic M, Stein-Streilein J, Zakarija M, McKenzie JM, Guffee J, Fletcher MA. Suppression of peripheral blood Natural Killer cell activity by excess thyroid hormone. J Clin Invest 1987; 79: 404–408.

    Article  PubMed  CAS  Google Scholar 

  8. Todd I, Pujol-Borrel R, Hammond LJ, Nally JM, Feldmann M, Botazzo GF. Enhancement of thyrocyte HLA class II expresion by thyroid-stimulating hormone. Clin Exp Immunol 1987;69:524–531.

    PubMed  CAS  Google Scholar 

  9. Rieu M, Richard A, Rosilio M. et al. Effects of thyroid status on thyroid autoimmunity expression in euthyroid and hypothyroid patients with Hashimoto’s thyroiditis. Clin Endocrinol 1994; 40: 529–535.

    Article  CAS  Google Scholar 

  10. Schmidt ED, Schmidt EDL, Van der Gaag R. et al. Distribution of the nuclear thyroid-hormone receptor in extraocular and skeletal muscles. J Endocrinol 1992; 133: 67–74.

    Article  PubMed  CAS  Google Scholar 

  11. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, Van der Gaag R. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Int Med 1990; 150: 1098–1101.

    Article  CAS  Google Scholar 

  12. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, Van der Gaag R. Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 1989; 121(Suppl.2): 185–189.

    Google Scholar 

  13. Weetman AP, Wiersinga WM. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey. Clin Endocrinol 1998; 49: 21–28.

    Article  CAS  Google Scholar 

  14. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R. Carbimazole and the autoimmune response in Graves’ disease. N Engl J Med 1980; 303: 302–307.

    Article  PubMed  CAS  Google Scholar 

  15. McGregor AM, Ibbertson HK, Rees Smith B, Hall R. Carbimazole and autoantibody synthesis in Hashimoto’s thyroiditis. Br Med J 1980; 281: 968–969.

    Article  PubMed  CAS  Google Scholar 

  16. Weetman AP, Holt ME, Campbell AK, Hall R, McGregor AM. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J 1984; 288: 518–520.

    Article  CAS  Google Scholar 

  17. Davies TF, Yang C, Platzer M. The influence of antithyroid drugs and iodine on thyroid cell MHC class II antigen presentation. Clin Endocrinol 1989; 31: 125–135.

    Article  CAS  Google Scholar 

  18. Pinchera A, Liberti P, Martino E. et al. Effects of antithyroid drug therapy on the long acting thyroid stimulator and antithyroglobulin antibodies. J Clin Endocrinol Metab 1969; 29:231–238.

    Article  PubMed  CAS  Google Scholar 

  19. Weetman AP. The immunomodulatory effects of antithyroid drugs. Thyroid 1994; 2: 145–146.

    Article  Google Scholar 

  20. Soloman B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 1990; 70: 1518–1524.

    Article  Google Scholar 

  21. DeGroot LJ. Radioiodine and the immune system. Thyroid 1997; 7: 259–264.

    Article  PubMed  CAS  Google Scholar 

  22. McGregor AM, Petersen MM, Capiferri R, Evered DC, Smith BR, Hall R. Effects of radioiodine on thyrotropin binding inhibiting immunoglobulins in Graves’ disease. Clin Endocrinol 1979; 11: 437–444.

    Article  CAS  Google Scholar 

  23. Pinchera A, Pinchera MG, Stanbury JB. Thyrotropin and long acting thyroid stimulator assays in thyroid disease. J Clin Endocrinol Metab 1965; 25: 189–208.

    Article  PubMed  CAS  Google Scholar 

  24. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. Br Med J 1993; 307: 828–832.

    Article  CAS  Google Scholar 

  25. Huysmans DAKC, Hermus ARMM, Edelbroek MAL. et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid 1997; 7: 535–539.

    Article  PubMed  CAS  Google Scholar 

  26. Teng WP, Stark R, Munro AJ, Young SM, Borysewicz LK, Weetman AP. Peripheral blood T cell activation after radioiodine treatment for Graves’ disease. Acta Endocrinol (Copenh) 1990; 122: 233–240.

    CAS  Google Scholar 

  27. Soliman M, Kaplan E, Abdel-Latif A, Scherberg N, DeGroot LJ. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients’ T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases? J Clin Endocrinol Metab 1995; 80: 2312–2321.

    Article  PubMed  CAS  Google Scholar 

  28. Bauer FK, Catz B. Radioactive iodine therapy for progressive malignant exophthalmos. Acta Endocrinol (Copenh ) 1966; 51: 15–22.

    CAS  Google Scholar 

  29. Werner SC, Feind CR, Aida M. Graves’ disease and total thyroidectomy. Progression of severe eye changes and decrease in serum Long Acting Thyroid Stimulator after operation. N Engl J Med 1967; 276: 132–137.

    Article  PubMed  CAS  Google Scholar 

  30. DeGroot LJ. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves’ ophthalmopathy. J Clin Endocrinol Metab 1995; 80: 339–340.

    Article  PubMed  CAS  Google Scholar 

  31. De Bruin TWA, Patwardhan A, Brown RS, Braverman LE. Graves’ disease: changes in TSH receptor and anti-microsomal antibodies after thyroidectomy. Clin Exp Immunol 1988; 72:481–485.

    PubMed  Google Scholar 

  32. Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 1987; 16: 391–407.

    PubMed  CAS  Google Scholar 

  33. Sridama V, DeGroot LJ. Treatment of Graves’ disease and the course of ophthalmopathy. Am J Med 1989; 87: 70–73.

    Article  PubMed  CAS  Google Scholar 

  34. Tallstedt L, Lundell G, Torring O. et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992; 326: 1733–1738.

    Article  PubMed  CAS  Google Scholar 

  35. Gorman CA. Radioiodine therapy does not aggravate Graves’ ophthalmopathy. J Clin Endocrinol Metab 1995; 80: 340–342.

    PubMed  CAS  Google Scholar 

  36. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994; 130: 494–497.

    Article  PubMed  CAS  Google Scholar 

  37. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349–1362.

    Article  PubMed  CAS  Google Scholar 

  38. Bartalena L, Marcocci C, Bogazzi F. et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 338: 73–78.

    Article  PubMed  CAS  Google Scholar 

  39. Wiersinga WM. Preventing Graves’ ophthalmopathy. N Engl J Med 1998; 338: 121–122.

    Article  PubMed  CAS  Google Scholar 

  40. Barth A, Probst P, Burgi H. Identification of a subgroup of Graves’ disease patients at higher risk for severe ophthalmopathy after radioiodine. J Endocrinol Invest 1991; 14: 209–212.

    PubMed  CAS  Google Scholar 

  41. Marcocci C, Bartalena L, Pinchera A. Ablative or non-ablative therapy for Graves’ hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998; 21: 468–471.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, F5-171, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Mark F. Prummel

Authors
  1. Mark F. Prummel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wilmar M. Wiersinga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudio Marcocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony P. Weetman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Endocrinology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Mark F. Prummel M.D. Ph.D.  & Wilmar M. Wiersinga M.D. Ph.D. (Professor of Endocrinology) &  (Professor of Endocrinology)

  2. Department of Ophthalmology, Orbital Center, University Medical Center Utrecht, Heidelberglaan 100, The Netherlands

    Maarten Ph. Mourits M.D. Ph.D.

  3. Zentrum für Innere Medizin mit Schwerpunkt Gastroenterologie, Endokrinologie, Diabetologie, Klinikum der Philipps-Universität Marburg, Baklingerstrasse, 35033, Marburg, Germany

    Armin E. Heufelder M.D. Ph.D. (Professor of Endocrinology) (Professor of Endocrinology)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Prummel, M.F., Wiersinga, W.M., Marcocci, C., Weetman, A.P. (2000). Thyroid management in Graves’ ophthalmopathy. In: Prummel, M.F., Wiersinga, W.M., Mourits, M.P., Heufelder, A.E. (eds) Recent Developments in Graves’ Ophthalmopathy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4647-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4647-4_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7102-1

  • Online ISBN: 978-1-4615-4647-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation